Project description:Microarray analysis of primary effusion lymphoma cell lines BC-1 and BC-3 Total RNA from BC-1 and BC-3 cell lines was processed for analysis in one replicate on Human Gene 1.0 ST arrays to obtain data on whether genes are expressed and to compare to existing microarray data.
Project description:Breast cancer (BC) is the leading cause of women's cancer death worldwide. Here, in the BC – Anti Progestin Prevention Study 1 (BC-APPS1; NCT02408770), we assess whether progesterone receptor antagonism with ulipristal acetate (UA) for 12 weeks reduces surrogate markers of BC risk in 24 premenopausal women. We employ a multi-layered OMICs and live-cell approach as readouts for molecular features alongside clinical imaging and tissue micro-mechanics correlates. UA reduced epithelial proliferation (Ki67) and the proportion, proliferation, and colony formation capacity of luminal progenitor (LP) cells, the precursors of aggressive BCs. MRI scans showed reduction in fibroglandular volume with treatment, while single-cell RNAseq, proteomics, histology and atomic force microscopy identified extracellular matrix remodelling with reduced collagen organisation and tissue stiffness. Laser capture targeted mass spectrometry revealed Ccollagen VI as the most significantly down-regulated protein after UA treatment and we uncovered an unanticipated spatial association between Collagen VI and Sox9hi LP cell localization, establishing a link between collagen organization and LP activity. This study offers a template for molecularly informed early phase prevention trials and demonstrates the potential for premenopausal BC prevention with progesterone receptor antagonists through stromal remodelling and LP suppression.
Project description:Waldenströms macroglobulinemia (WM) is a rare lymphoproliferative disorder with apparent morphologic and immunophenotypic heterogeneity and its origins are still poorly understood. In this study, using Gene-Expression Profiling (GEP), we compared the global mRNA expression patterns of CD19+ WM B cells (WM-BC) and CD138+ WM plasma cells (WM-PC) with those of normal CD19+ peripheral blood B cells (PB-BC), tonsil-BC (T-BC), CD138+ T-PC and bone marrow PC (N-PC). Experiment Overall Design: The sample cohort studied consisted of CD19-selected peripheral blood B cells (PB-BC; n = 7), tonsil B cells (T-BC; n = 7), bone marrow B cells from WM (WM-BC; n = 12), tonsil plasma cells (T-PC; n = 9), bone marrow plasma cells from healthy donors (N-PC; n = 10), WM plasma cells (WM-PC, n = 9), and MM plasma cells (MM-PC; n = 11).
